Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

Francisco Bautista; Angelo Paci; Veronique Minard-Colin; Christelle Dufour; Jacques Grill; Ludovic Lacroix; Pascale Varlet; Dominique Valteau-Couanet; Birgit Geoerger

doi:10.1002/pbc.24891

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

Francisco Bautista, Angelo Paci, Veronique Minard-Colin, Christelle Dufour, Jacques Grill, Ludovic Lacroix, Pascale Varlet, Dominique Valteau-Couanet, Birgit Geoerger

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

129 Citations (Scopus)

Résumé

We present three pediatric patients with BRAFV600E mutant high-grade gliomas treated by vemurafenib on a nominative authorization level at our institution. One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start of treatment. A second patient with ganglioglioma responded transiently to re-introduction of vemurafenib after immunotherapy. Pharmacokinetic studies suggest that maximum concentration and exposure of vemurafenib at steady-state is dose-dependent and similar in children to that reported in adults. These cases suggest that BRAFV600 is an oncogenic driver in pediatric gliomas. Further exploration in clinical studies is ongoing. Pediatr Blood Cancer 2014;61:1101-1103.

langue originale	Anglais
Pages (de - à)	1101-1103
Nombre de pages	3
journal	Pediatric Blood and Cancer
Volume	61
Numéro de publication	6
Les DOIs	https://doi.org/10.1002/pbc.24891
état	Publié - 1 janv. 2014
Modification externe	Oui

Accès au document

10.1002/pbc.24891

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{0a348508d4da4f9a8515c7ab2a5d77a7,

title = "Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas",

abstract = "We present three pediatric patients with BRAFV600E mutant high-grade gliomas treated by vemurafenib on a nominative authorization level at our institution. One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start of treatment. A second patient with ganglioglioma responded transiently to re-introduction of vemurafenib after immunotherapy. Pharmacokinetic studies suggest that maximum concentration and exposure of vemurafenib at steady-state is dose-dependent and similar in children to that reported in adults. These cases suggest that BRAFV600 is an oncogenic driver in pediatric gliomas. Further exploration in clinical studies is ongoing. Pediatr Blood Cancer 2014;61:1101-1103.",

keywords = "Anaplastic ganglioglioma, BRAF mutations, Pediatric brain tumors, Pharmacokinetics, Vemurafenib",

author = "Francisco Bautista and Angelo Paci and Veronique Minard-Colin and Christelle Dufour and Jacques Grill and Ludovic Lacroix and Pascale Varlet and Dominique Valteau-Couanet and Birgit Geoerger",

year = "2014",

month = jan,

day = "1",

doi = "10.1002/pbc.24891",

language = "English",

volume = "61",

pages = "1101--1103",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "6",

}

TY - JOUR

T1 - Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

AU - Bautista, Francisco

AU - Paci, Angelo

AU - Minard-Colin, Veronique

AU - Dufour, Christelle

AU - Grill, Jacques

AU - Lacroix, Ludovic

AU - Varlet, Pascale

AU - Valteau-Couanet, Dominique

AU - Geoerger, Birgit

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We present three pediatric patients with BRAFV600E mutant high-grade gliomas treated by vemurafenib on a nominative authorization level at our institution. One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start of treatment. A second patient with ganglioglioma responded transiently to re-introduction of vemurafenib after immunotherapy. Pharmacokinetic studies suggest that maximum concentration and exposure of vemurafenib at steady-state is dose-dependent and similar in children to that reported in adults. These cases suggest that BRAFV600 is an oncogenic driver in pediatric gliomas. Further exploration in clinical studies is ongoing. Pediatr Blood Cancer 2014;61:1101-1103.

AB - We present three pediatric patients with BRAFV600E mutant high-grade gliomas treated by vemurafenib on a nominative authorization level at our institution. One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start of treatment. A second patient with ganglioglioma responded transiently to re-introduction of vemurafenib after immunotherapy. Pharmacokinetic studies suggest that maximum concentration and exposure of vemurafenib at steady-state is dose-dependent and similar in children to that reported in adults. These cases suggest that BRAFV600 is an oncogenic driver in pediatric gliomas. Further exploration in clinical studies is ongoing. Pediatr Blood Cancer 2014;61:1101-1103.

KW - Anaplastic ganglioglioma

KW - BRAF mutations

KW - Pediatric brain tumors

KW - Pharmacokinetics

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84899473817&partnerID=8YFLogxK

U2 - 10.1002/pbc.24891

DO - 10.1002/pbc.24891

M3 - Article

C2 - 24375920

AN - SCOPUS:84899473817

SN - 1545-5009

VL - 61

SP - 1101

EP - 1103

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

ER -